MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Prima Biomed (PBMD) CVac Platform Has Great Potential 0 comments
    Jan 24, 2014 11:14 AM | about stocks: PBMD

    Prima Biomed is a leader in developing personalized immunocellular therapeutics that deal with cancer. It has a flagship product known as the CVac vaccine that targets mucin-1 overexpressing cancer cells. It is a first or second-line treatment for epithelial ovarian cancer in remission.


    This is the company's "personalized immunocellular therapeutic" treatment for epithelial ovarian cancer. The treatment stimulates the patient's own immune system to target and destroy tumors. The treatment is customized for each patient and works as follows:

    • The patient's own immune precursors are isolated from their blood

    • The patient's blood is circulated through a special filter that takes out only the cells needed to produce the immunocellular therapeutic

    • These cells are matured in the laboratory and treated with a tumor-specific cell surface protein called mucin 1

    • The unique form of mucin 1 is present in great amounts on epithelial ovarian tumors

    • The CVac then moves through the patient's blood stream, and as CVac comes in contact with immune cells (T cells), it activates them to recognize and subsequently destroy tumor cells producing the tumor form of mucin 1 protein

    CANVAS Clinical Trial

    The CANcer VAccine Study ("CANVAS") is a phase 2 study of epithelial ovarian cancer patients. The study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumor progression. It also hopes to extend the overall survival of patients.

    The CANVAS study represents a major investment by Prima in the future of the CVac program for ovarian cancer. Prima has spent significant resources as it gets ready to begin this trial. The highest quality training and cell collection procedures will be in place to assure a smooth scale up in the manufacturing of CVac.

    Ovarian Cancer Market Data

    • Ovarian Cancer has an overall incidence of 35,000 per year between the US and EU7

    • Current standard of care is debulking/platinum/Taxane/chemo

    • Care has not changed in 20 years

    In the United States, the market is about 20,000 patients alone. There needs to be a more effective therapy that can be tolerated and avoid the side effects of the present acceptable treatments. For a treatment that can address these issues, the potential market size is $1.0 billion annually.

    Ovarian Cancer's Treatment Challenge

    Prima's ovarian cancer market is quite a challenge. In a typical clinical journey, cancer patients will see periods of remission and relapse of shortening duration until a resistance to chemotherapy develops. Most women being treated for ovarian cancer respond positively with "first-line" treatment. But the treatment is not long-lasting. Seven out of 10 patients end up dying of a recurrence of the cancer within five years of diagnosis. There is a lack of second-line therapy for patients who relapse.

    One important note for investors is that the second-line treatment looked fine and is being investigated further. When analyzing the potential market size, second-line treatment is going to be the majority of research the company is looking for anyway. Investors are waiting for more input into the first-line treatment which will probably have its trial restarted sometime in the first quarter of 2014.

    It is protected from bio-similar competition, and intends to seek Orphan designation for enhanced exclusivity in the US and EU.

    For a small-cap company, it has an extremely strong cash balance. As of the end of the last quarter, the company had approximately $30 million in cash. Most of the research and development in 2013 was centered on ongoing clinical trials for Cvac in ovarian cancer and for its personalized immunocellular therapeutic platform.

    Prima Biomed is a small-cap stock with a platform that has strong revenue potential. It has good data and efficacy in a huge ovarian cancer market. If the data comes out favorably in 2014, it would not be surprising if Prima's share price finally took off. At that point, investors are likely going to enjoy some long-term success.

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: PBMD
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.